Pharmacokinetic/pharmacodynamic indices: Are we ready to use them in daily practice?

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 6, 2007, Pages 913-916

  Grau, Satiago ^a   Álvarez Lerma, Francisco ^b   Domínguez Gil, Alfonso ^c  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPUTER PROGRAM; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG PENETRATION; DRUG TREATMENT FAILURE; DRUG USE; EDITORIAL; HUMAN; INFECTION; INFORMATION SCIENCE; MATHEMATICAL MODEL; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PATHOPHYSIOLOGY; PREDICTION; PRESCRIPTION;

ANIMALS; ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 37349012186     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.6.913     Document Type: Editorial

References (9)

1. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addresssing the issue of appropriate pneumonia treatment in critically ill patients? Clin. Infect. Dis. 42, 1764-1771 (2006).
2. Craig WA. Pharmacokinetic/pharmacodinamic parameters: rationale for antibiotic dosing of mice and men. Clin. Infect. Dis. 26, 1-10 (1998).
3. Mueller M, de la Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48, 369-377 (2004).
4. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. 44, 357-363 (2007).
5. Sanchez-Navarro A, Sanchez Recio MM. Basis of anti-infective therapy: pharmacokinetic - pharmacodynamic criteria and methodology for dual dosage individualisation. Clin. Pharmacokinet. 37, 289-304 (1999).
6. Astigarraga PM, Montero J, Grau-Cerrato S et al. GEIPC-SEIMC and [GTEI-SEMICYUC recommendations for antibiotic treatment of Gram positive coccal infections in the critical patient]. Enferm. Infecc. Microbiol. Clin. 25, 446-466 (2007).
7. Zahar JR, Rioux C, Girou E et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J. Antimicrob. Chemother. 58, 651-656 (2006).
8. Bakker-Woudenberg IAJM, ten Kate MT, Goessens WHF, Mouton JW. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumonia lung infection. Antimicrob. Agents Chemother. 50, 2919-2925 (2006).
9. Burton ME, Shaw LM, Schentang JJ, Evans WE. Applied Pharmacokinetics Pharmacodynamics. Principles of Therapeutic Drug Monitoring. Lippincott Williams & Wilkins, MD, USA (2006).